Kymera – Talk Bio

Kymera Snags Gilead as New Partner; Sanofi Opts for Next-Gen IRAK4 Degrader

4 weeks ago talkbio0Tagged biotech collaborations, CDK2 protein, human, Degrader, Gilead Sciences, IRAK4 gene, Kymera, Malignant neoplasm of breast, Molecular Glue Degrader, oncology partnership, sanofi, Solid Neoplasm

Kymera Therapeutics; Gilead Sciences; Sanofi; molecular glue degrader; CDK2; solid tumors; breast cancer; oncology partnership; IRAK4 degrader; biotech collaborations

Kymera Faces Sanofi Setback but Secures $750M Gilead Oncology Deal

4 weeks ago talkbio0Tagged CDK2 protein, human, Gilead, Kymera, Molecular Glue Degrader, Neoplasms, protein degrader, sanofi

Kymera; Sanofi; Gilead; molecular glue degrader; CDK2; oncology; deal; protein degrader

Kymera Soars on Early Protein Degrader Data

2 months ago talkbio0Tagged Autoimmune Diseases, Clinical Trials, KT-621, Kymera, Phase 1 (qualifier value), Protein Degradation, Metabolic, STAT6 degrader

Kymera Therapeutics; KT-621; STAT6 degrader; protein degradation; Phase 1 clinical trial; autoimmune disease

Kymera Therapeutics Shifts Focus to Immunology, Scaling Back Oncology Efforts

9 months ago talkbio0Tagged Immunology, IRAK4 gene, Kymera, Neoplasms, Protein Degradation, Metabolic, STAT6, TYK2 gene

Kymera Therapeutics, Immunology, Oncology, Targeted Protein Degradation, IRAK4, STAT6, TYK2